NicOx
 |
|
| Société Anonyme | |
| Traded as | Euronext: COX |
| Industry | Pharmaceuticals |
| Founded | 1996 |
| Headquarters | Sophia Antipolis, France |
|
Key people
|
Michele Garufi (Chairman of the board) |
| Products | Naproxcinod |
| Revenue |
 €3,36 million (2009) |
|
€73,887 million (2008) |
|
| Total equity |
€102,069 million (2009) |
|
Number of employees
|
133 (2009) |
| Subsidiaries | NicOx Research Institute Srl, NicOx Inc. |
| Website | www |
NicOx S.A. is a French pharmaceutical company. Its headquarters are at Sophia Antipolis (U.S. headquarters in Warren, New Jersey, opened in October 2007). Louis Ignarro, co-recipient of the 1998 Nobel Prize in Physiology or Medicine for demonstrating the signalling properties of nitric oxide, is a member of the scientific committee of the company and Bengt Samuelsson, Nobel laureate 1982 serves as director on the company board.
The company focuses on the uses of the medical properties of nitric oxide. It has several molecules in the pipeline, and its lead compound was an anti-inflammatory drug, naproxcinod, of the CINOD (COX-inhibiting nitric oxide donator) class for the treatment of osteoarthritis. This class of drugs was first described by Dr. John L. Wallace and colleagues. The company has ongoing development partnerships with Bausch & Lomb and Merck.
NicOx was financed with venture capital provided by a syndicate including Apax France, Sofinnova, Auriga and HealthCap. The company went public on the Paris Stock Exchange in 1999. The market capitalisation of the company was $1 billion as of January 2008. It is listed on Euronext, the French stock exchange and is part of the CAC Mid 100 . It has been included in the SBF 120 index since 18 June 2007. Oppenheimer Funds is its first shareholder with 25% of its capital.
...
Wikipedia